Organon & Co. has grown revenue −0.22% a year over three years and −0.64% a year over five, with earnings per share compounding at −36%. Revenue growth, 3-year annual rate: −0.22% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: −0.64%, growth has picked up over the last three years. Earnings per share, 3-year rate: −36%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 7, FY2019 to FY2025, as filed.

OGNOrganon & Co.

HealthcareUSD

$13.77

$5.6952 weeks$13.77

Is it growing?

Is OGN growing?

Organon & Co. has grown revenue −0.22% a year over three years and −0.64% a year over five, with earnings per share compounding at −36%.

−0.22%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −0.64%
Revenue growth, 5-year rate · −0.22% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −36%
Earnings per share, 3-year rate · revenue −0.22% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed